Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review.
nuclear model calculation
nuclear reaction cross section
radionuclides of copper
standardisation of nuclear data
theranostic approach
thick target yield
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
07
2023
accepted:
08
09
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules. This characteristic makes it suitable for applications in molecular imaging or radionuclide targeted therapy. Of particular interest in nuclear medicine today is the theranostic approach. This brief review considers five radionuclides of copper. These are Cu-60, Cu-61, Cu-62, Cu-64, and Cu-67. The first four are positron emitters for imaging, and the last one Cu-67 is a β
Identifiants
pubmed: 37841203
doi: 10.3389/fchem.2023.1270351
pii: 1270351
pmc: PMC10570421
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1270351Informations de copyright
Copyright © 2023 Hussain, Qaim, Spahn, Aslam and Neumaier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Appl Radiat Isot. 2016 Feb;108:38-48
pubmed: 26686974
Appl Radiat Isot. 2014 Sep;91:38-43
pubmed: 24886964
J Nucl Med. 1998 Nov;39(11):1958-64
pubmed: 9829589
Curr Pharm Des. 2007;13(1):3-16
pubmed: 17266585
Appl Radiat Isot. 2012 Mar;70(3):423-9
pubmed: 22142633
Appl Radiat Isot. 2014 Feb;85:101-13
pubmed: 24389533
Front Med (Lausanne). 2022 May 18;9:889640
pubmed: 35665337
Appl Radiat Isot. 2012 Sep;70(9):1894-9
pubmed: 22406222
Appl Radiat Isot. 2012 Oct;70(10):2377-83
pubmed: 22871441
Molecules. 2022 Feb 23;27(5):
pubmed: 35268600
Appl Radiat Isot. 2023 May;195:110737
pubmed: 36863264
Nucl Med Biol. 2018 Apr;59:56-60
pubmed: 29475187
Appl Radiat Isot. 2017 Nov;129:6-12
pubmed: 28783614
Appl Radiat Isot. 2014 Dec;94:131-140
pubmed: 25169133
Appl Radiat Isot. 2009 Oct;67(10):1842-54
pubmed: 19640722
Appl Radiat Isot. 2003 Nov-Dec;59(5-6):343-51
pubmed: 14622933
Int J Rad Appl Instrum A. 1986;37(1):29-36
pubmed: 3019924
Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1473-80
pubmed: 16258764
Front Med (Lausanne). 2021 Jul 05;8:674617
pubmed: 34291060
Nucl Med Biol. 1996 Nov;23(8):957-80
pubmed: 9004284
Nucl Med Biol. 1999 May;26(4):351-8
pubmed: 10382836
Appl Radiat Isot. 2002 Jun;56(6):821-31
pubmed: 12102338
J Labelled Comp Radiopharm. 2018 Jul;61(9):636-651
pubmed: 29341227
Nucl Med Biol. 2017 Jan;44:31-49
pubmed: 27821344
Nucl Med Biol. 1997 Jan;24(1):35-43
pubmed: 9080473
Appl Radiat Isot. 2014 Jul;89:65-73
pubmed: 24607530
Appl Radiat Isot. 2019 Feb;144:124-129
pubmed: 30579152
Appl Radiat Isot. 2020 Nov;165:109338
pubmed: 32795775
Appl Radiat Isot. 2013 Feb;72:169-76
pubmed: 23220029
J Nucl Med. 1993 Dec;34(12):2222-6
pubmed: 8254415
Pharmaceuticals (Basel). 2017 Jun 20;10(2):
pubmed: 28632200
Sci Rep. 2023 Jul 13;13(1):11326
pubmed: 37443187